Michael Lee

Array ( [id] => 11602402 [patent_doc_number] => 20170119702 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-04 [patent_title] => 'Dosage Regimen of Diaryl Sulfide Derivatives' [patent_app_type] => utility [patent_app_number] => 15/297683 [patent_app_country] => US [patent_app_date] => 2016-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 6934 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15297683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11419741 [patent_doc_number] => 20170027885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => '1-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF COCHLEAR TINNITUS' [patent_app_type] => utility [patent_app_number] => 15/291527 [patent_app_country] => US [patent_app_date] => 2016-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 11192 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15291527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14069209 [patent_doc_number] => 20190083492 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => TOPICAL MINOXIDIL COMPOSITION [patent_app_type] => utility [patent_app_number] => 15/765249 [patent_app_country] => US [patent_app_date] => 2016-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2073 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15765249 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11401641 [patent_doc_number] => 20170022179 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-26 [patent_title] => 'COMPOSITIONS, DOSAGES, AND METHODS OF USING TETRAHYDROCANNABINOL DERIVATIVES' [patent_app_type] => utility [patent_app_number] => 15/284106 [patent_app_country] => US [patent_app_date] => 2016-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10190 [patent_no_of_claims] => 56 [patent_no_of_ind_claims] => 50 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15284106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16009021 [patent_doc_number] => 20200179353 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => MEDICINAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY RESPIRATORY DISEASE [patent_app_type] => utility [patent_app_number] => 15/772901 [patent_app_country] => US [patent_app_date] => 2016-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4014 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15772901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15632035 [patent_doc_number] => 10588985 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-17 [patent_title] => Compositions and methods relating to RAD6 inhibition [patent_app_type] => utility [patent_app_number] => 15/755386 [patent_app_country] => US [patent_app_date] => 2016-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 27 [patent_no_of_words] => 11513 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15755386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16105471 [patent_doc_number] => 10695320 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-30 [patent_title] => Compositions comprising urolithin compounds [patent_app_type] => utility [patent_app_number] => 15/757293 [patent_app_country] => US [patent_app_date] => 2016-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 9710 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15757293 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13410029 [patent_doc_number] => 20180256557 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => PHARMACEUTICAL COMBINATION COMPRISING (A) THE ALPHA-ISOFORM SPECIFIC PI3K INHIBITOR ALPELISIB (BYL719) AND (B) AN AKT INHIBITOR, PREFERABLY MK-2206, AFURESERTIB OR UPROSERTIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER [patent_app_type] => utility [patent_app_number] => 15/754649 [patent_app_country] => US [patent_app_date] => 2016-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10797 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15754649 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13368789 [patent_doc_number] => 20180235935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => Treatment of Cancer with Enzalutamide and a CYP3A4 Inhibitor [patent_app_type] => utility [patent_app_number] => 15/751542 [patent_app_country] => US [patent_app_date] => 2016-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3887 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15751542 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15751153 [patent_doc_number] => 10617658 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-14 [patent_title] => Use of hydroxycarbamide for preventing retinal nonperfusion [patent_app_type] => utility [patent_app_number] => 15/750143 [patent_app_country] => US [patent_app_date] => 2016-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 6181 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15750143 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13339663 [patent_doc_number] => 20180221371 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => TREATMENT FOR THE FETUS WITH CONGENITAL HEART DISEASE [patent_app_type] => utility [patent_app_number] => 15/749792 [patent_app_country] => US [patent_app_date] => 2016-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6791 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15749792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11289055 [patent_doc_number] => 20160338986 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-24 [patent_title] => 'METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AUDITORY DYSFUNCTIONS' [patent_app_type] => utility [patent_app_number] => 15/230257 [patent_app_country] => US [patent_app_date] => 2016-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 30416 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15230257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14387265 [patent_doc_number] => 10306886 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-04 [patent_title] => Lactam solubility [patent_app_type] => utility [patent_app_number] => 15/750910 [patent_app_country] => US [patent_app_date] => 2016-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1824 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15750910 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13386149 [patent_doc_number] => 20180244616 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => LACTAM COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 15/750890 [patent_app_country] => US [patent_app_date] => 2016-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2432 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15750890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13368865 [patent_doc_number] => 20180235973 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => LIQUID FORMULATIONS OF FOSAPREPITANT [patent_app_type] => utility [patent_app_number] => 15/750068 [patent_app_country] => US [patent_app_date] => 2016-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2952 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15750068 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13297365 [patent_doc_number] => 20180200219 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => PHEROMONE COMPOSITIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/748671 [patent_app_country] => US [patent_app_date] => 2016-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5715 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15748671 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13383495 [patent_doc_number] => 20180243289 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => DEUTERATED MORPHINAN COMPOUNDS FOR TREATING AGITATION [patent_app_type] => utility [patent_app_number] => 15/748804 [patent_app_country] => US [patent_app_date] => 2016-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10820 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15748804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13354411 [patent_doc_number] => 20180228745 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => SUBSTANCE SELECTED AMONG MIDODRINE, A PHARMACEUTICAL SALT AND AN ACTIVE METABOLITE THEREOF, FOR USE IN THE TREATMENT OF OBSTRUCTIVE CARDIOPATHY [patent_app_type] => utility [patent_app_number] => 15/747890 [patent_app_country] => US [patent_app_date] => 2016-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7947 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15747890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16009053 [patent_doc_number] => 20200179369 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => TREATMENT OF DIABETIC NEPHROPATHY [patent_app_type] => utility [patent_app_number] => 15/746560 [patent_app_country] => US [patent_app_date] => 2016-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16975 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15746560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13339605 [patent_doc_number] => 20180221342 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => HEPATITIS C VIRUS INHIBITORS [patent_app_type] => utility [patent_app_number] => 15/749557 [patent_app_country] => US [patent_app_date] => 2016-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20731 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15749557 [rel_patent_id] =>[rel_patent_doc_number] =>)